We recently published a list of 13 Best Cheap Dividend Stocks To Buy Right Now. In this article, we are going to take a look ...

Kepler Capital analyst David Evans maintained a Buy rating on Merck KGaA (0O14 – Research Report) on March 6 and set a price target of ...

With increasing biomarker-driven cancer treatments, TEPMETKO benefits from growing adoption in precision oncology. Competition from other MET inhibitors like TABRECTA (capmatinib) exists, but ...

Elsewhere in the obesity space — Amgen has initiated Phase 3 trials of its obesity drug MariTide, one in overweight and obese ...

German science and technology company Merck on Thursday forecast its net sales to be in the range of €21.5 billion ($23.2 ...

The state of Delaware has offered Merck a $30.2 million grant to encourage the company to choose the Wilmington-area location. If Merck accepts the grant, the company would be required to create 375 ...

The company has asked the U.S. patent office to reconsider patents that could prevent it from selling an update to Keytruda.

Merck KGaA on Thursday forecast currency-adjusted operating earnings growth of up to 8%, helped by demand for semiconductor ...

Merck KGaA expects earnings and sales growth this year after reporting a rise in annual earnings on temporarily reduced ...

The increasing occurrence of chronic and infectious diseases is the main driver of the rising demand for interferon. Furthermore, advancements in interferon production and ongoing research and ...

Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech ...